JOVAN POPOVICH: Open Payments
NPI 1396384707 · PEABODY, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,036 in 53 payments from 16 companies in 2025. Trend: 2023 $185 · 2024 $423 · 2025 $1,036
Food & beverage: $1,036
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $156 |
| Lundbeck LLC | 12 | $148 |
| Vanda Pharmaceuticals Inc. | 6 | $145 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| ABBVIE INC. | 5 | $105 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| Alkermes, Inc. | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| HARMONY BIOSCIENCES LLC | 1 | $35 |
Products named: REXULTI, INGREZZA, FANAPT, VRAYLAR, CAPLYTA, COBENFY, ABILIFY ASIMTUFII, Auvelity.
Industry payments across MA — which companies pay providers there.
